Q-Line Biotech Ltd.

•

qlinebiotech.comBSE: -NSE: QLINE

Market Cap₹ 1,694 Cr.

Current Price

High / Low₹ 730 / 431

Stock P/E30.4

Book Value₹ 91

Price to Book8.00

Dividend Yield0.00 %

ROCE22.2 %

ROE25.6 %

Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Manufacturing: 67.4% • Trading: 32.6%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Operating margins have improved to 27.1% from 19.6%
Attractively priced for its growth - PEG of 0.8

CONS

Receivables are growing faster than sales - a possible quality concern
Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.10x)
Free cash flow has been persistently negative
Equity base is being diluted - shares outstanding up 933.3%
Working capital days have increased from 100 to 135 days
Total debt has risen sharply - up 35.6% year on year

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcareMedical Equipment/Supplies/Accessories

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	LENSKART	681.75	180.93	118577.20	0.00	2284.30	3634.35	27141.80	1332.69	12.55	21.70
2.	POLYMED	1737.35	55.89	17610.03	0.20	85.27	-8.39	525.38	30.30	14.05	24.11
3.	MOLBIO	1441.60	99.72	16613.00	0.00	527.44	—	4083.76	—	19.79	24.63
4.	QLINE	726.20	30.40	1694.09	0.00	—	—	—	—	22.23	—
5.	3BBLACKBIO	1423.95	22.01	1222.13	0.35	8.98	-28.99	33.49	50.59	26.03	25.45
6.	LAXMIDENTL	201.95	35.98	1111.32	0.00	10.32	23.83	74.70	16.13	24.96	20.26
7.	GKB	63.70	9.90	32.11	0.00	1.85	387.99	33.04	2.26	8.82	7.97

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

No quarterly results found

We don't have this information yet. Please check back later.

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	183	204	313	342
	149	166	252	244
Operating Profit	34	38	62	98
OPM %	18.47%	18.69%	19.68%	28.71%
	2	3	-5	5
Interest	4	6	15	19
Depreciation	2	4	7	11
Profit before Tax	30	31	35	73
Tax %	28.34%	29.28%	54.86%	23.20%
Net Profit	21	22	16	56
EPS	20.38	218.73	121.98	34.24
Dividend Payout %	0.00%	0.00%	0.00%	0.00%

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: —
3 Years:: 23%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: 20%

STOCK PRICE CAGR

10 Years:: —
5 Years:: —
3 Years:: —
1 Year:: —

RETURN ON EQUITY

10 Years:: —
5 Years:: —
3 Years:: 16%
Last Year:: 26%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	2	2	16
	126	160	188	230
	69	86	141	188
Trade Payables	40	59	56	52
	15	32	68	72
Total Liabilities	251	339	455	558
	23	60	74	142
Capital Work in Progress	12	19	59	15
	16	29	18	17
	44	105	90	95
	0	26	83	126
Cash & Bank	90	30	47	76
	67	69	84	87
Total Assets	251	339	455	558

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	37	-24	17	16
Cash from Investing	-26	-45	-77	-29
Cash from Financing	26	17	53	42
	25	-52	-7	29

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	May 2026
	67.51
	1.67
	9.50
Government	0.00
	21.32

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

No announcements filed.

News

Recent coverage and analyst commentary for QLINE

Loading news…

🤖

AI Stock Analyst

Q-Line Biotech Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

LENSKART

681.75

180.93

118577.20

0.00

2284.30

3634.35

27141.80

1332.69

12.55

21.70

POLYMED

1737.35

55.89

17610.03

0.20

85.27

-8.39

525.38

30.30

14.05

24.11

MOLBIO

1441.60

99.72

16613.00

0.00

527.44

—

4083.76

—

19.79

24.63

QLINE

726.20

30.40

1694.09

0.00

—

22.23

—

3BBLACKBIO

1423.95

22.01

1222.13

0.35

8.98

-28.99

33.49

50.59

26.03

25.45

LAXMIDENTL

201.95

35.98

1111.32

0.00

10.32

23.83

74.70

16.13

24.96

20.26

GKB

63.70

9.90

32.11

0.00

1.85

387.99

33.04

2.26

8.82

7.97

Mar 2023

Mar 2024

Mar 2025

Mar 2026

183

204

313

342

149

166

252

244

Operating Profit

OPM %

18.47%

18.69%

19.68%

28.71%

-5

Interest

Depreciation

Profit before Tax

Tax %

28.34%

29.28%

54.86%

23.20%

Net Profit

EPS

20.38

218.73

121.98

34.24

Dividend Payout %

0.00%

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Equity Capital

126

160

188

230

141

188

Trade Payables

Total Liabilities

251

339

455

558

142

Capital Work in Progress

105

126

Cash & Bank

Total Assets

251

339

455

558

Mar 2023

Mar 2024

Mar 2025

Mar 2026

-24

Cash from Investing

-26

-45

-77

-29

Cash from Financing

-52

-7

Mar 2023

Mar 2024

Mar 2025

Mar 2026

May 2026

67.51

1.67

9.50

Government

0.00

21.32

Q-Line Biotech Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Q-Line Biotech Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI